Effects of dinuclear copper(II) complexes with 6-(benzylamino)purine derivatives on AhR and PXR dependent expression of cytochromes P450 CYP1A2 and CYP3A4 genes in primary cultures of human hepatocytes
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
19854261
DOI
10.1016/j.tiv.2009.10.012
PII: S0887-2333(09)00313-0
Knihovny.cz E-resources
- MeSH
- Benzyl Compounds chemistry toxicity MeSH
- Cytochrome P-450 CYP1A2 genetics metabolism MeSH
- Cytochrome P-450 CYP3A genetics metabolism MeSH
- Adult MeSH
- Hepatocytes drug effects metabolism MeSH
- Cells, Cultured MeSH
- Middle Aged MeSH
- Humans MeSH
- Copper chemistry toxicity MeSH
- RNA, Messenger genetics metabolism MeSH
- Molecular Structure MeSH
- Pregnane X Receptor MeSH
- Purines chemistry toxicity MeSH
- Receptors, Aryl Hydrocarbon metabolism MeSH
- Gene Expression Regulation, Enzymologic drug effects MeSH
- Aged MeSH
- Receptors, Steroid metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- benzylaminopurine MeSH Browser
- Benzyl Compounds MeSH
- CYP1A2 protein, human MeSH Browser
- CYP3A4 protein, human MeSH Browser
- Cytochrome P-450 CYP1A2 MeSH
- Cytochrome P-450 CYP3A MeSH
- Copper MeSH
- RNA, Messenger MeSH
- Pregnane X Receptor MeSH
- Purines MeSH
- Receptors, Aryl Hydrocarbon MeSH
- Receptors, Steroid MeSH
A series of dinuclear copper(II) complexes of the compositions [Cu(2)(micro-L(n))(2)(micro-Cl)(2)Cl(2)] (1, 2), [Cu(2)(micro-L(n))(4)Cl(2)]Cl(2).2H(2)O (3, 4) and [Cu(2)(micro-L(n))(4)(ClO(4))(2)](ClO(4))(2).xSolv (5, 6; xSolv=4MeOH for 5 and 2EtOH for 6), involving 6-(benzylamino)purine derivatives (L(n)), have been evaluated with the aim to determine their possible drug interactions and their capability to induce the expression of major drug-metabolizing cytochromes P450. The above-mentioned complexes have been chosen based on the fact that substantial both in vitro (cytotoxicity, SOD-mimic) and in vivo (antidiabetic) biological activity has been found for them. As models, primary cultures of human hepatocytes and human hepatoma cells HepG2 transiently transfected with a plasmid containing dioxin-responsive element fused to the luciferase reporter gene (DRE-LUC) have been chosen. It has been found that the tested complexes 1-6 did not significantly induce the expression of CYP1A2 and CYP3A4 mRNAs in the concentration range of 0.1-10.0microM, in three different primary human hepatocyte cultures after 24h of the treatment. On the other hand, the model inducers, i.e. 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) and rifampicin, significantly increased the levels of CYP1A2 and CYP3A4 mRNAs in all cultures. In addition, compounds 1-6 did not transactivate DRE-LUC in transiently transfected HepG2, while TCDD strongly induced luciferase activity after 24h of incubation. Based on the obtained results, it may be concluded that the studied dinuclear copper(II) complexes 1-6 possess very low toxicological potential to cause drug interactions in terms of transcriptional activation of the major human cytochromes P450.
References provided by Crossref.org
Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene
